MT Newswires
Arcus Biosciences Insider Sold Shares Worth $1,203,959, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
4/10
as of 12-23-2025 3:46pm EST
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
| Founded: | 2015 | Country: | United States |
| Employees: | 674 | City: | HAYWARD |
| Market Cap: | 2.9B | IPO Year: | 2018 |
| Target Price: | $29.38 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.50 - $26.40 | Next Earning Date: | 10-28-2025 |
| Revenue: | $240,000,000 | Revenue Growth: | -8.74% |
| Revenue Growth (this year): | -5.86% | Revenue Growth (next year): | -41.20% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Accounting Officer
Avg Cost/Share
$22.25
Shares
4,343
Total Value
$96,613.51
Owned After
18,531
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$22.16
Shares
9,983
Total Value
$221,218.29
Owned After
193,024
SEC Form 4
President
Avg Cost/Share
$22.16
Shares
9,983
Total Value
$221,218.29
Owned After
346,012
SEC Form 4
Chief Accounting Officer
Avg Cost/Share
$22.16
Shares
2,113
Total Value
$46,823.02
Owned After
18,531
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$22.16
Shares
25,744
Total Value
$570,474.17
Owned After
2,194,809
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$22.16
Shares
5,960
Total Value
$132,070.62
Owned After
74,476
SEC Form 4
General Counsel
Avg Cost/Share
$22.16
Shares
6,810
Total Value
$150,906.20
Owned After
124,734
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$22.16
Shares
4,494
Total Value
$99,584.79
Owned After
65,647
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$21.88
Shares
11,225
Total Value
$245,651.27
Owned After
193,024
SEC Form 4
President
Avg Cost/Share
$21.88
Shares
11,225
Total Value
$245,651.27
Owned After
346,012
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Azoy Alexander | RCUS | Chief Accounting Officer | Dec 18, 2025 | Sell | $22.25 | 4,343 | $96,613.51 | 18,531 | |
| Jarrett Jennifer | RCUS | Chief Operating Officer | Dec 17, 2025 | Sell | $22.16 | 9,983 | $221,218.29 | 193,024 | |
| Jaen Juan C. | RCUS | President | Dec 17, 2025 | Sell | $22.16 | 9,983 | $221,218.29 | 346,012 | |
| Azoy Alexander | RCUS | Chief Accounting Officer | Dec 17, 2025 | Sell | $22.16 | 2,113 | $46,823.02 | 18,531 | |
| ROSEN TERRY J | RCUS | Chief Executive Officer | Dec 17, 2025 | Sell | $22.16 | 25,744 | $570,474.17 | 2,194,809 | |
| Goeltz II Robert C. | RCUS | Chief Financial Officer | Dec 17, 2025 | Sell | $22.16 | 5,960 | $132,070.62 | 74,476 | |
| Tang Carolyn C. | RCUS | General Counsel | Dec 17, 2025 | Sell | $22.16 | 6,810 | $150,906.20 | 124,734 | |
| Markus Richard | RCUS | Chief Medical Officer | Dec 17, 2025 | Sell | $22.16 | 4,494 | $99,584.79 | 65,647 | |
| Jarrett Jennifer | RCUS | Chief Operating Officer | Dec 16, 2025 | Sell | $21.88 | 11,225 | $245,651.27 | 193,024 | |
| Jaen Juan C. | RCUS | President | Dec 16, 2025 | Sell | $21.88 | 11,225 | $245,651.27 | 346,012 |
RCUS Breaking Stock News: Dive into RCUS Ticker-Specific Updates for Smart Investing
AI Sentiment
Neutral
4/10
AI Sentiment
Negative
3/10
AI Sentiment
Negative
2/10
AI Sentiment
Neutral
4/10
AI Sentiment
Positive
6/10
See how RCUS stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "RCUS Arcus Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.